Clinical trial
Phase I First-in-Human Study of MC001 (ADoBind Dimeric IgG-Monomethyl Auristatin E), a First-in-Class Dimeric Antibody-Drug Conjugate Targeting Folate Receptor Alpha (FRα), in Patients With Advanced Solid Tumours
NCT07929961 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, Phase 1, 80 participants (estimated). Lead sponsor National University Hospital, Singapore; Singapore. Primary measures: Incidence of Adverse Events (AEs); Incidence of Serious Adverse Events (SAEs) and 4 more.
How it compares
47 similar trials: same condition (Nasopharyngeal Carcinoma) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I First-in-Human Study of MC001 (ADoBind Dimeric IgG-Monomethyl Auristatin E), a First-in-Class Dimeric Antibody-Drug Conjugate Targeting Folate Receptor Alpha (FRα), in Patients With Advanced Solid Tumours
- Lead sponsor
- National University Hospital, Singapore
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 16, 2026
- Completion date
- November 30, 2031
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumours, nasopharyngeal carcinoma, pancreatic ductal adenocarcinoma (pdac)
Arms
As registered; 9 arms.
-
Dose Level 1
0.3 mg/kg
-
Dose Level 2
0.6 mg/kg
-
Dose Level 3
1.0 mg/kg
-
Dose Level 4
1.6 mg/kg
-
Dose Level 5
2.2 mg/kg
+4 more arms
Primary endpoints
Registered primary outcome measures; 6 primary.
-
Incidence of Adverse Events (AEs)
Incidence and severity of adverse events (AEs) occurring during the study period, assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0. CTCAE grades range from Grade 1 (mild) to Grade 5 (death related to an adverse event).
-
Incidence of Serious Adverse Events (SAEs)
Number of participants experiencing one or more serious adverse events (SAEs) during the study period.
-
Incidence of dose-limiting toxicities
Number of participants experiencing a dose-limiting toxicity (DLT) during Cycle 1. DLTs are protocol-defined adverse events occurring during the first 21 days of treatment that are considered at least possibly related to the study drug and are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0.
-
Maximum Tolerated Dose (MTD)
The maximum tolerated dose (MTD) is determined using the modified Toxicity Probability Interval (mTPI-2) design and is defined as the highest dose level at which the observed rate of dose-limiting toxicities (DLTs) during Cycle 1 does not exceed the prespecified target toxicity probability.
-
Maximum Administered Dose (MAD)
The maximum administered dose (MAD) is determined as the highest dose level of MC001 evaluated during the dose-escalation phase, regardless of whether a maximum tolerated dose (MTD) is reached.
+1 more primary endpoint
Lead sponsor's other trials
National University Hospital, Singapore, most recent start first.
+448 more trials
Similar trials
Same condition (Nasopharyngeal Carcinoma) and phase, most recent start first.
+42 more trials See the condition page